Introduction Sodium-glucose cotransporter-2 inhibitors (SGLT2i), initially introduced for glycaemic control in type 2 diabetes, have transformed heart failure (HF) management by demonstrating cardiovascular and renal benefits independent of glucose lowering (1). In heart failure with reduced ejection fraction (HFrEF, LVEF <40%), large randomized co
Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure
150 Reached
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Patient with History of Atrial Fibrillation
519 Reached3 Likes
FOURIER Trial: Efficacy of Evolocumab in Managing Cardiovascular Events
563 Reached3 Comments